Alberto Grignolo, VP of global strategy and services told Outsourcing-pharma.com that “twenty years ago the name of the game was running clinical trials in the US and Europe…nowadays companies begin drug development with the world in mind.”
Dr Grignolo explained that this means developers must interact with a greater number of regulatory bodies worldwide, which in turn is driving demand for contract research organisations (CRO) that can assist in this process.
“This creates opportunities to be creative,” he continued “clients want to take medicines to the world and they are looking for partners, such as Parexel, that can help them do this.”